The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
On May 29, Bristol Myers Squibb announced that its experimental drug mezigdomide delayed disease progression in a late-stage trial for multiple myeloma patients. The results showed that the drug reduces the risk of disease by 52%. These findings represent a significant advancement in the treatment of this type of cancer.